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OBJECTIVES: Chronic hepatitis B (CHB) is a major health problem in Taiwan where
an estimated two million people are infected with the virus, with many being
untreated. The disease is associated with a high risk of long term hepatic compli-
cations including cirrhosis and hepatocellular carcinoma (HCC). Treatment with
anti-virals such as entecavir reduces the risk of complications andmay lead to long
term cost savings. The aim of this economicmodelling studywas to investigate the
socioeconomic burden of untreated CHB in Taiwan and assess the economic ben-
efits of treatment. METHODS: A Markov model was developed that comprised
health states describing themanagement and consequences of CHB. Data from the
Taiwanese observational REVEAL cohort were used to estimate the risk of CHB
complications. Direct costs of complicationswere derived from literature and prev-
alence estimates were included to calculate the burden of disease amongst 30-59
year olds eligible for treatment in Taiwan. The model compared the economic
impact of doubling the number of eligible patients treated with entecavir on the
incidence of hepatic complications and associated costs. Themodelwas conducted
from a Taiwanese payer perspective with a 40 year time horizon. RESULTS: Treat-
ment of more eligible patients reduced the number of CHB complications over 40
years and was associated with a 1.06% (NTD 9.1 billion) reduction in total costs for
all diagnosed patients. Inclusion of productivity losses accentuated this with rela-
tive cost savings of 1.68% (NTD 17.2 billion). Based upon this setting, cost savings
would be realised by year 15. CONCLUSIONS: CHB is likely to have a substantial
economic impact over the next 40 years in Taiwan. Treating a greater proportion of
patients could alleviate this burden and lead to cost savings. Furthermore, treating
more patients is predicted to reduce productivity losses, improve quality of life,
and reduce mortality.
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OBJECTIVES: To estimate the budgetary consequence of adding Ustekinumab to
the reimbursement drug list in Thailand. METHODS: From payer’s perspective, a
5-year budget impact model was developed based on the current treatment algo-
rithm and reimbursement criteria for moderate to severe chronic plaque psoriasis.
We assumed the current biologic reimbursement program for psoriasis in civil
servant medical benefit scheme (CSMBS) was expanded to cover all Thai popula-
tion. Annual budget impact assessment was a result of changes of current mix of
biologic therapies by introduction of Ustekinumab. This use is as 1st or 2nd biologic
agent in patients with inadequate response from systemic therapies or other bio-
logics, respectively. Current and future market mix data of biologic therapies was
estimated by experts’ opinions, and products’ efficacy and epidemiology data was
derived from literature. Cost variables included medical care costs: biologic acqui-
sition costs, physician visits, monitoring lab tests and inadequate response care.
Univariate sensitivity analysis was conducted to assess the model robustness.
RESULTS: Ustekinumab’s inclusion showed the average total budget spending of
260 million baht per year (226 – 309 million baht from 1st - 5th year respectively).
Comparing to current scenarios with two biologics available, we found the dimi-
nution of total budget around 81 million baht in 5-yr period, accounting for 0.14
million baht per patient. Average budget growth rate was slightly lower with the
inclusion of Ustekinumab (9.90% vs. 11.75%). Comparative total cost per responder
was found lowest in Ustekinumab followed by Infliximab and Etanercept respec-
tively. These results weremainly driven by the number of patients on biologics and
distribution of patients among the available therapies. CONCLUSIONS: The addi-
tion of Ustekinumab to the current biologic reimbursement list provides more
efficient management approach for the treatment budget of moderate to severe
chronic plaque psoriasis in Thailand.
PSY9
MEDICAL COST OF ORGAN DAMAGE DUE TO SYSTEMIC LUPUS
ERYTHEMATOSUS
Chiu YM1, Lang HC2, Chuang MT2
1Changhua Christian Hospital, Changhua City, Changhua County, Taiwan, 2National Yang-Ming
University, Taipei, Taiwan
OBJECTIVES: Systemic lupus erythematosus(SLE) is a chronic autoimmune disor-
der that may affect basically every organ of the body, such as the skin, joints,
kidneys, lungs and nervous system. The aim of this study was to demonstrate the
cost of organ damage cause by SLE. METHODS: A population-based dataset from
the Taiwan’s National Health Insurance Research Dataset (NHIRD) from 2006 to
2010 was used to collect SLE caused organ damage related medical cost. The cases
of SLE were identified according to the ICD-9-CM code 710.0 and catastrophic ill-
ness certificates. SLE related organ damage condition is defined based on the Sys-
temic Lupus International Collaborative Clinics/American Rheumatology (SLICC/
ACR) Damage Index, which contains 41 damage items in 12 systems that are
specific comorbidities associated with SLE or damage due to toxicity of SLE treat-
ment. ICD-9-CM codes were also used for organ damage conditions. To avoid dou-
ble-counting, SLE cases were only included if single comorbidity is observed.
RESULTS:A total number of 22,258 SLE patients were identified and used to extract
cost data of organ damage. Number of prevalent cases increased from 14,748 in
2006 to 18,047 in 2010, and prevalence rates permillion populations increased from
644.7 (623.0 after adjustment) in 2006 to 779.2 (729.9 after adjustment) in 2010.
Among 41 damage items, two of them (shrinking lung andminor tissue loss) do not
have corresponding ICD-9-CM codes. Recurrent cerebral vascular accident or re-
section, cardiomyopathy, and recurrent myocardial infarction caused most medi-
cal expenditures, and mean costs incurred in the first year were NT$ 502,171, NT$
498,871, and NT$ 357,979, respectively. CONCLUSIONS: Organ damages caused by
SLE have incurred tremendous resource utilization to health care system in Tai-
wan. New treatment which can avoid organ damages with neuropsychiatric, renal
and cardiovascular systems is needed for SLE patients.
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OBJECTIVES: Parenteral nutrition is a form of nutritional support administered via
an intravenous catheter. Kabiven is a simple TPN solution that consists of a three
chamber bag and the individual chambers contain glucose- and amino acid solu-
tions, and fat emulsion, respectively. Kabiven may effect serum albumin levels for
malnutrition patient and cost savings to patients receiving tradition TPN.
METHODS: This was a retrospective study in a regional hospital from January 1,
2011 to December 31, 2011. We collected data on patients admitted to ward care
programs who are consulted TPN group for nutrition suggest, a total 164 who are
consulted TPN group than received kabiven for nutrition support during their hos-
pitalization.Monitor serumalbuminwas performed before and after kabiven given
were rospective criteria. RESULTS: The 164 patient included 108 male ( 65.9%) and
56 female (34.1%) GAverage length of stay was 14.3 days (10-30 days; 51.2%) GAver-
age age at 77.2y/o (70-79y/o,33%). The result elevated serum albumin levels 39%(
1.2 g/dl, 25% G0.8 g/dl, 17%G0.7 g/dl, 15%), same serum albumin level 44%,
decrease serum albumin levels 17%. CONCLUSIONS: This study demonstrated that
the simple TPN solutions (kabiven) may significant elevated serum albumin levels
for malnutrition patient and significant cost savings to patients receiving tradition
TPN.
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OBJECTIVES: To describe the prevalence and the treatment status of hemophilia A
(HA), hemophilia B (HB) andVonWillebrand disease (VWD) in India, Russia, Taiwan
and Turkey based on existing data, and to compare prophylaxis with on-demand
therapy. METHODS: We conducted a systematic literature review in Aug, 2011
using PubMed, EMBASE, and Cochrane Library. No retrieval limitation was set. We
also carried out general and targeted internet searches of hemophilia related web-
sites. Reference lists of key reviews were hand-searched for further researches.
Studies providing data of prevalence, treatment or cost of hemophilia in India,
Russia, Taiwan and Turkey were included. Noteexpress 2 was used to manage the
literatures. Meta-analysis was done using the generic inverse variance model.
RESULTS:Overall, 7 epidemiological and 15 economic studieswere included for the
analysis. The prevalence of hemophilia in India, Russia, Taiwan and Turkey was
2.27 per 100 000 (HAHB), 5.12 per 100 000 (HAHBVWD), 3.61 per 100 000 (HA)
and 4.93 per 100 000 (HAHBVWD) respectively. In India, about 15% patients
received no treatment, 47.5% patients used previous blood transfusion, 12.5% used
cryoprecipitate and 25% used factor concentrate. 37% of patients used prophylaxis
in Russia. In Turkey, prophylaxis was superior to on-demand therapy even when
given in a twice-weekly period with intermediate concentrates. Annual extra ex-
penditure of below $5000 per case with prophylaxis compared to on-demand ther-
apywould be needed to permit hemophiliac children to achieve similar capacity as
unaffected ones. In Taiwan, approximately $2 million per year would be added to
the cost of treatment by having all severe HA patients receive secondary prophy-
laxis instead of on-demand therapy while 12566 bleeding would be prevented.
CONCLUSIONS: The prevalence of hemophilia is different among those 4 districts.
Hemophiliacs lack adequate treatment generally. It is practical to switch from
on-demand therapy to Prophylaxis.
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OBJECTIVES: To explore peri-operative bleeding and its relationship with patient
morbidity, mortality and increased health care costs in Hong Kong. METHODS:
EMBASE andMedline databaseswere searched to identify relevant epidemiological
and economic studies. To ensure pertinence of the data, only studies published in
the last 15 years were considered. Relevant studies were identified using a priori
defined inclusion criteria relating to the patient population, setting and outcomes
of interest. RESULTS: Eighteen studies were included in this systematic review.
Themean volume of blood loss ranged from 20–2200mL. Laparoscopic procedures
were generally associated with lower blood loss (20–350 mL), while orthognathic
and liver surgery were associated with greater blood loss (600–2200 mL). Similarly,
the mean volume of blood transfused varied by surgical procedure ranging from
0.17 units (head and neck surgery) to 1.8 units (orthognathic surgery).With the cost
of 1 unit of whole blood estimated at US$200 in Hong Kong, the need for transfu-
sions potentially represent a substantial cost to patients and the health care sys-
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